...
首页> 外文期刊>Dalton transactions: An international journal of inorganic chemistry >Non-nitric oxide based metallovasodilators: synthesis, reactivity and biological studies
【24h】

Non-nitric oxide based metallovasodilators: synthesis, reactivity and biological studies

机译:非一氧化氮基金属扩容剂:合成,反应性和生物学研究

获取原文
获取原文并翻译 | 示例
           

摘要

There is an increasing number of compounds developed to target one or more pathways involved in vasodilation. Some studies conducted with azaindole and indazole derivatives showed cardiovascular activity associated with these compounds. Fast and easy structural modification of these organic molecules can be achieved using metal complexes promoting a much larger spatial change than organic strategies, potentially leading to novel drugs. Here, we have prepared a series of complexes with a formula cis-[RuCl(L)(bpy)(2)]PF6, where L = 7-azaindole (ain), 5-azaindole (5-ain), 4-azaindole (4-ain), indazole (indz), benzimidazole (bzim) or quinoline (qui), which were characterized by spectroscopic and electrochemical techniques (CV, DPV). These compounds showed reasonable stability exhibiting photoreactivity only at low wavelength along with superoxide scavenger activity. Cytotoxicity assays indicated their low activity preliminarily supporting in vivo application. Interestingly, vasodilation assays conducted in rat aorta exhibited great activity that largely improved compared to free ligands and even better than the well-studied organic compound (BAY 41-42272), with IC50 reaching 55 nM. These results have validated this strategy opening new opportunities to further develop cardiovascular agents based on metallo-bicyclic rings.
机译:已经开发出越来越多的化合物以靶向血管舒张涉及的一种或多种途径。用氮杂吲哚和吲唑衍生物进行的一些研究表明,与这些化合物有关的心血管活性。使用金属配合物可以促进比有机策略更大的空间变化,从而实现对这些有机分子的快速简便结构修饰,从而有可能产生新药。在这里,我们制备了一系列具有式cis- [RuCl(L)(bpy)(2)] PF6的配合物,其中L = 7-氮杂吲哚(ain),5-氮杂吲哚(5-ain),4-氮杂吲哚(4-氨基),吲唑(indz),苯并咪唑(bzim)或喹啉(qui),已通过光谱和电化学技术(CV,DPV)进行了表征。这些化合物显示出合理的稳定性,仅在低波长下显示光反应性以及超氧化物清除剂活性。细胞毒性测定表明它们的低活性初步支持体内应用。有趣的是,在大鼠主动脉中进行的血管舒张试验显示出强大的活性,与游离配体相比,活性大大提高,甚至比经过充分研究的有机化合物(BAY 41-42272)更好,IC50达到55 nM。这些结果证实了该策略为进一步开发基于金属双环的心血管药物开辟了新的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号